P2Y11 Antagonist B7508: Evidence-Based Utility in Cell Signaling and Immunology Research

Executive Summary: The P2Y11 antagonist (B7508) is a chemically defined inhibitor of the P2Y11 receptor, used primarily for mechanistic studies in cell signaling and immunology (APExBIO). Its molecular formula (C37H26N4Na4O15S4) and high water solubility (<19.74 mg/ml) enable reproducible experimental preparation. Peer-reviewed research demonstrates its capacity to reverse QPRT-induced breast cancer invasiveness (Liu et al., 2021). Proper storage at -20°C and prompt use after solution preparation are essential for stability. The reagent is not suitable for diagnostic or therapeutic use, restricting its application to laboratory research.

Biological Rationale

The P2Y11 receptor is a purinergic G protein-coupled receptor (GPCR) expressed in various immune cell types, including monocytes and T lymphocytes (Liu et al., 2021). It mediates signaling via ATP binding, activating downstream cAMP and Ca²⁺ mobilization pathways. Dysregulated P2Y11 signaling has been linked to abnormal immune responses, neuroinflammation, and cancer cell invasiveness. In breast cancer models, upregulation of purinergic signaling components—including P2Y11—correlates with enhanced migration and invasiveness. Selective antagonists like B7508 are critical for dissecting these pathways in vitro and in vivo (See advanced mechanisms; this article extends by focusing on verifiable benchmarks and parameterization).

Mechanism of Action of P2Y11 antagonist

The P2Y11 antagonist B7508 functions as a competitive inhibitor of the P2Y11 receptor. Upon binding, it prevents endogenous agonists such as ATP from activating the receptor, thereby blocking associated G_s and G_q-mediated signaling cascades. This inhibition leads to reduced intracellular cAMP generation and impaired calcium mobilization. In cell-based assays, B7508 abrogates signaling events downstream of P2Y11 activation, including phosphorylation of myosin light chain (MLC), a process linked to cell motility and invasiveness (Liu et al., 2021).

Evidence & Benchmarks

• P2Y11 antagonist (B7508) at 10 μM reverses QPRT-induced invasiveness and myosin light chain phosphorylation in MDA-MB-231 breast cancer cells (Liu et al., 2021, Table 2).
• Inhibition of P2Y11 signaling disrupts Rho/ROCK/MLCK pathways, reducing cell migration in vitro (Liu et al., 2021, Figure 4).
• B7508 demonstrates high water solubility (<19.74 mg/ml at RT, neutral pH), facilitating preparation for cell-based assays (APExBIO product data).
• Stability is maintained for at least 12 months at -20°C as a dry solid, but aqueous solutions should be used immediately (APExBIO).
• The compound is not cytotoxic at concentrations up to 10 μM in standard breast cancer lines, as assessed by MTT assay (Liu et al., 2021, Supplementary Data).

Applications, Limits & Misconceptions

B7508 is optimized for research on GPCR signaling, immunology, and inflammation. It has been used to model purinergic signaling in breast cancer and to investigate autoimmune disease mechanisms (Previous work focused on breast cancer models; this article updates with additional experimental benchmarks.). The reagent is not suitable for diagnostic or therapeutic use and is not validated for in vivo pharmacology.

Common Pitfalls or Misconceptions

• Not a clinical drug: B7508 is strictly for laboratory research; no human or animal therapeutic applications are approved (APExBIO).
• Does not inhibit all P2Y receptors: B7508 is selective for P2Y11; it does not block other P2Y subtypes at standard concentrations (Liu et al., 2021).
• Solution stability is limited: Aqueous solutions degrade rapidly at ambient temperature; always prepare fresh (APExBIO).
• No direct anti-proliferative effects: It does not exert cytotoxicity at functional concentrations in standard in vitro models (Liu et al., 2021).
• Not a universal inflammation inhibitor: Effects are context-dependent and mediated only via P2Y11 pathways.

Workflow Integration & Parameters

The P2Y11 antagonist is supplied as a beige solid, with a molecular weight of 986.84 g/mol. For cell-based assays, dissolve in sterile water to a final concentration below 19.74 mg/ml. Store all dry material at -20°C. Use blue ice for shipping and minimize solution storage time to preserve activity. Integrating B7508 into signaling pathway studies enables clear dissection of ATP-mediated GPCR effects. For protocol optimization, see the Advanced Strategies for GPCR Signaling guide; this article provides experimental parameters to complement troubleshooting advice.

Conclusion & Outlook

The P2Y11 antagonist B7508 from APExBIO is a robust tool for dissecting GPCR signaling in immunology and cancer research. Its defined chemical profile, storage guidelines, and validated selectivity enable highly reproducible experiments. As new purinergic signaling roles are uncovered, B7508's use is expected to expand in autoimmune and neuroinflammation models (Prior systems biology perspectives; this article updates with direct experimental evidence and best practices).

For ordering and further technical details, visit the P2Y11 antagonist B7508 product page.